Milestone Pharmaceuticals (MIST) CFO updates 204,000-share option to $1.96

Rhea-AI Filing Summary

Milestone Pharmaceuticals Inc. insider filing: the company’s CFO and EVP of Corporate Development reported an amended employee stock option grant. The filing corrects the exercise price for an option to buy 204,000 common shares at $1.96 per share, granted on February 2, 2026 and expiring on February 2, 2036. One-fourth of the option vests on February 2, 2027, with the remaining shares vesting in equal monthly installments over the following 36 months while the executive continues providing service.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Hasija Amit

(Last) (First) (Middle)

C/O MILESTONE PHARMACEUTICALS INC.

1111 DR. FREDERIK-PHILIPS BLVD, STE 420

(Street)

MONTREAL A8 H4M 2X6

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Milestone Pharmaceuticals Inc. [ MIST ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CFO & EVP of Corp. Development

3. Date of Earliest Transaction (Month/Day/Year)
02/02/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)
02/04/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock Option (right to buy)	$1.96(1)	02/02/2026		A		204,000		(2)	02/02/2036	Common Shares	204,000	$0	204,000	D

Explanation of Responses:

1. The exercise price on the initial filings was incorrectly stated.

2. One-fourth (1/4th) of the shares subject to the option vest on February 2, 2027, and one thirty-sixth (1/36th) of the remaining shares subject to this option shall vest each month thereafter, subject to the Reporting Person continuing to provide service through each such date.

	/s/ Joseph Oliveto, Attorney-in-Fact	02/05/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Milestone Pharmaceuticals (MIST) report on this Form 4/A?

Milestone Pharmaceuticals reported an amended employee stock option grant for its CFO and EVP of Corporate Development. The amendment covers an option for 204,000 common shares, correcting the exercise price and confirming the vesting schedule and expiration terms originally disclosed.

How many shares are covered by the amended stock option for Milestone (MIST)’s CFO?

The amended employee stock option covers 204,000 common shares of Milestone Pharmaceuticals. This option was granted on February 2, 2026 and is structured to vest over time, subject to the executive’s continued service with the company through each applicable vesting date.

What is the corrected exercise price of the Milestone (MIST) stock option in this Form 4/A?

The corrected exercise price of the employee stock option is $1.96 per share. The filing notes that the exercise price reported on the initial filings was incorrect, and this amendment updates the terms while keeping the grant size and vesting structure the same.

When does the amended Milestone (MIST) stock option begin vesting and when does it expire?

One-fourth of the option shares vest on February 2, 2027. The remaining shares vest in equal monthly installments over the following 36 months, and the option expires on February 2, 2036, assuming continued service by the reporting executive throughout the vesting period.

Who is the reporting person in the Milestone Pharmaceuticals (MIST) Form 4/A filing?

The reporting person is an officer of Milestone Pharmaceuticals serving as CFO and EVP of Corporate Development. The filing reflects this executive’s amended stock option grant and clarifies the corrected exercise price and vesting schedule associated with the reported derivative security.

Why was an amendment (Form 4/A) necessary for this Milestone (MIST) option grant?

An amendment was necessary because the exercise price on the initial filings was incorrectly stated. This Form 4/A corrects that specific term, restating the employee stock option’s exercise price while reaffirming the original grant date, share amount, vesting terms, and expiration date.